Isolation of a Klebsiella pneumoniae Isolate of Sequence Type 258 Producing KPC-2 Carbapenemase in Korea.
10.3343/kjlm.2011.31.4.298
- Author:
Kyoung Ho ROH
1
;
Chang Kyu LEE
;
Jang Wook SOHN
;
Wonkeun SONG
;
Dongeun YONG
;
Kyungwon LEE
Author Information
1. Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
KPC-2;
Klebsiella pneumoniae;
ST258
- MeSH:
Aged;
Bacterial Proteins/antagonists & inhibitors/metabolism;
Carbapenems/pharmacology;
Drug Resistance, Bacterial/genetics;
Female;
Humans;
Klebsiella pneumoniae/drug effects/genetics/*isolation & purification;
Microbial Sensitivity Tests;
Republic of Korea;
Sequence Analysis, DNA;
Urinary Tract Infections/*diagnosis/microbiology;
beta-Lactamases/antagonists & inhibitors/biosynthesis/*genetics/metabolism
- From:The Korean Journal of Laboratory Medicine
2011;31(4):298-301
- CountryRepublic of Korea
- Language:English
-
Abstract:
Carbapenem-resistant Klebsiella pneumoniae isolates producing K. pneumoniae carbapenemases (KPC) were first reported in the USA in 2001, and since then, this infection has been reported in Europe, Israel, South America, and China. In Korea, the first KPC-2-producing K. pneumoniae sequence type (ST) 11 strain was detected in 2010. We report the case of a patient with a urinary tract infection caused by KPC-2-producing K. pneumoniae. This is the second report of a KPC-2-producing K. pneumoniae infection in Korea, but the multilocus sequence type was ST258. The KPC-2-producing isolate was resistant to all tested beta-lactams (including imipenem and meropenem), amikacin, tobramycin, ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole, but was susceptible to gentamicin, colistin, polymyxin B, and tigecycline. The KPC-2-producing isolate was negative to phenotypic extended-spectrum beta-lactamase (ESBL) and AmpC detection tests and positive to modified Hodge test and carbapenemase inhibition test with aminophenylboronic acid.
